On March 24, 2014, Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) issued a press release announcing its financial results for the three months ended December 31, 2013 and the year ended December 31, 2013. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) shares after opening at $44.87 moved to $44.87 on last trade day and at the end of the day closed at $42.56. Company price to cash ratio as 20.10. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) showed a negative weekly performance of -26.54%.
OXiGENE, Inc. (NASDAQ:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, on 7 April announced results from three preclinical studies related to its ongoing research and development programs. The data are being presented this week at the Annual Meeting of the American Association for Cancer Research (AACR) in San Diego, California. OXiGENE Inc. (NASDAQ:OXGN) shares fell -6.04% in last trading session and ended the day on $2.80. OXGN return on equity ratio is recorded as -212.60% and its return on assets is -180.80%. OXiGENE Inc. (NASDAQ:OXGN) yearly performance is -20.68%.
Net operating cash flow has remained constant at -$4.67 million with no significant change when compared to the same quarter last year. Even though there was no significant change, Idera Pharmaceuticals Inc. (NASDAQ:IDRA) cash flow growth rate is severely below the industry average. Idera Pharmaceuticals Inc. (NASDAQ:IDRA) shares moved down -5.78% in last trading session and was closed at $2.77, while trading in range of $2.74 – $3.09. Idera Pharmaceuticals Inc. (NASDAQ:IDRA) year to date (YTD) performance is -40.17%.
Inovio Pharmaceuticals (NYSE:INO) CEO Jong Joseph Kim bought 25,000 shares of the company’s stock in a transaction dated Tuesday, April 15th. The shares were purchased at an average price of $2.25 per share, for a total transaction of $56,250.00. Following the transaction, the chief executive officer now directly owns 5,965,809 shares of the company’s stock, valued at approximately $13,423,070. Inovio Pharmaceuticals Inc. (NYSEMKT:INO) weekly performance is -16.00%. On last trading day company shares ended up $2.52. Inovio Pharmaceuticals Inc. (NYSEMKT:INO) distance from 50-day simple moving average (SMA50) is -21.44%. Analysts mean target price for the company is $4.60.
Leave a Reply